Search research articles
Contact Us
Filters
Showing results (191-200 of 225) with videos related to
Page
of 23
Sort By:
Journal of Medical Genetics
|
June 17, 2003
Spectrum of NSD1 mutations in Sotos and Weaver syndromes
M Rio, L Clech, J Amiel, et al.
Journal of Medical Genetics
|
April 6, 2001
Use of a set of highly polymorphic minisatellite probes for the identification of cryptic 1p36.3 deletions in a large collection of patients with idiopathic mental retardation
F Giraudeau, L Taine, V Biancalana, et al.
Clinical Oral Investigations
|
July 10, 2020
Re-focusing on Agnathia-Otocephaly complex
C Dubucs, N Chassaing, C Sergi, et al.
American Journal of Human Genetics
|
October 12, 2001
Large-scale deletions and SMADIP1 truncating mutations in syndromic Hirschsprung disease with involvement of midline structures
J Amiel, Y Espinosa-Parrilla, J Steffann, et al.
Neurology
|
September 2, 2011
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma
M Weller, T Gorlia, J G Cairncross, et al.
Journal of the National Cancer Institute
|
January 30, 2009
Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy
J L Lefebvre, F Rolland, M Tesselaar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 16, 2011
Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group
R Stupp, A Tosoni, J E C Bromberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 25, 2003
European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme
M J van den Bent, W Grisold, D Frappaz, et al.
British Journal of Cancer
|
August 23, 2012
Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin
A Ploquin, D Olmos, D Lacombe, et al.
Nature Genetics
|
February 1, 1997
A human homologue of the Drosophila eyes absent gene underlies branchio-oto-renal (BOR) syndrome and identifies a novel gene family
S Abdelhak, V Kalatzis, R Heilig, et al.
Page
of 23
Search research articles
Search
Showing results (191-200 of 225) with videos related to
Sort By:
Page
of 23
Journal of Medical Genetics
|
June 17, 2003
Spectrum of NSD1 mutations in Sotos and Weaver syndromes
M Rio, L Clech, J Amiel, et al.
Journal of Medical Genetics
|
April 6, 2001
Use of a set of highly polymorphic minisatellite probes for the identification of cryptic 1p36.3 deletions in a large collection of patients with idiopathic mental retardation
F Giraudeau, L Taine, V Biancalana, et al.
Clinical Oral Investigations
|
July 10, 2020
Re-focusing on Agnathia-Otocephaly complex
C Dubucs, N Chassaing, C Sergi, et al.
American Journal of Human Genetics
|
October 12, 2001
Large-scale deletions and SMADIP1 truncating mutations in syndromic Hirschsprung disease with involvement of midline structures
J Amiel, Y Espinosa-Parrilla, J Steffann, et al.
Neurology
|
September 2, 2011
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma
M Weller, T Gorlia, J G Cairncross, et al.
Journal of the National Cancer Institute
|
January 30, 2009
Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy
J L Lefebvre, F Rolland, M Tesselaar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 16, 2011
Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group
R Stupp, A Tosoni, J E C Bromberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 25, 2003
European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme
M J van den Bent, W Grisold, D Frappaz, et al.
British Journal of Cancer
|
August 23, 2012
Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin
A Ploquin, D Olmos, D Lacombe, et al.
Nature Genetics
|
February 1, 1997
A human homologue of the Drosophila eyes absent gene underlies branchio-oto-renal (BOR) syndrome and identifies a novel gene family
S Abdelhak, V Kalatzis, R Heilig, et al.
Page
of 23